Market Newsdesk

NEW YORK, Jan. 13, 2021 /PRNewswire/ — Enabling banks and wealth management firms to better leverage data through artificial intelligence (AI), Broadridge Financial Solutions, Inc. (NYSE:BR), a global Fintech leader, has announced a collaboration with AI company Fligoo to develop a suite of proprietary predictive analytics software products for the wealth management industry. These new software solutions will help banks and wealth management firms transform their business performance by harnessing vast amounts of data to accurately predict the needs of each client, creating a more personalized and customized client and investor experience.

Fligoo is an enterprise AI company that helps industry leaders boost their business performance. Fligoo Sharp AI Enterprise Suite software delivers exponential business value through state-of-the-art advanced analytics, monitoring, closed-loop feedback and decision science. The first product under development with Broadridge will allow financial advisors to take a data-driven approach to optimizing and enhancing their relationship with investors, both personalizing service and delivering in a manner and time preferred by clients. Fligoo and Broadridge anticipate that the hyper-personalization of investor needs will increase both client satisfaction and asset growth for the long-term across the entire investor base.

“We’re excited to leverage Broadridge’s extensive wealth management expertise, insights and data to develop software that can create genuine innovation in the wealth management industry,” said Lucas Olmedo, CEO of Fligoo. “We have condensed the expertise acquired on hundreds of use cases in multiple industries into a product that has the power to augment the capacity/performance of advisors, firms and investors on a daily basis.”     

“Investors expect advisors to understand their specific needs, and we are creating an end-to-end practice management solution with Fligoo that uses AI to enable financial advisors to anticipate investor needs at every moment of the investment life cycle,” said Michael Alexander, President of Wealth Management at Broadridge. “Together, we are creating an entire predictive analytics suite that will enable advisors to personalize and digitize their client engagements in a way that will deepen and broaden relationships in a more scalable manner.”

Leveraging these next-gen technologies is part of Broadridge’s investment in The ABCDs of Innovation® – AI, blockchain, the Cloud and digital – helping clients and the industry move markets forward into the future. Broadridge and Fligoo plan to launch additional AI-powered software products over the next year that deliver insights to wealth management firms and their advisors.

About Fligoo

Fligoo is an Enterprise AI Company that helps industry leaders boost their business performance by using AI to predict their customers’ behaviour and providing them with the products and services they need, when and how they need them.

Fligoo Sharp Enterprise AI Suite delivers exponential business value for enterprises around the world through state-of-the-art advanced analytics, monitoring, closed-loop feedback, & decision science.  Fligoo Sharp AI Enterprise Suite is a comprehensive end-to-end SaaS platform enabling the speedy development, deployment, testing, and scaling of large AI applications.

For more information about Fligoo, please visit www.fligoo.com.

About Broadridge

Broadridge Financial Solutions, Inc. (NYSE: BR), a $4 billion global Fintech leader, is a leading provider of investor communications and technology-driven solutions to banks, broker-dealers, asset and wealth managers and corporate issuers. Broadridge’s infrastructure underpins proxy voting services for over 50 percent of public companies and mutual funds globally, and processes on average more than U.S. $8 trillion in fixed income and equity securities trades per day. Broadridge is part of the S&P 500® Index and employs over 12,000 associates in 17 countries.

For more information about Broadridge, please visit www.broadridge.com.

Investors:

W. Edings Thibault
Head of Investor Relations, Broadridge
+1 516-472-5129
[email protected]

Media:

Tina Wadhwa

Corporate Communications, Broadridge
+1 212-973-6164
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/broadridge-partners-with-ai-company-fligoo-providing-innovative-predictive-analytics-to-wealth-management-301207281.html

SOURCE Broadridge Financial Solutions, Inc.

SAN DIEGO, Jan. 13, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that patient recruitment has commenced in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma (GBM).  The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a revolutionary, patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. 

Key GBM AGILE Highlights for VAL-083

• Only therapeutic agent currently being evaluated in all three GBM patient subtypes: newly-diagnosed methylated MGMT; newly-diagnosed unmethylated MGMT; and recurrent
• May accelerate VAL-083’s time to pivotal trial completion and potential regulatory submission by up to 18 months
• Cost-effective opportunity to advance VAL-083 due to the GBM AGILE study’s expense sharing protocol
• Anticipating rapid enrollment, targeting 150-200 patients with 34 active and recruiting U.S. sites with plans to increase to 40 sites during Q1, 2021, including Canada and other international locations to follow

“The entire Kintara team is grateful and excited to participate in GCAR’s groundbreaking GBM AGILE study as it offers an extraordinary opportunity to facilitate the advancement of VAL-083’s clinical development in a premier GBM study,” commented Saiid Zarrabian, Kintara’s Chief Executive Officer.  “This is truly an important milestone for Kintara as we believe the study will generate important insights into the breadth of VAL-083’s potential to address this deadliest form of brain cancer in all patient subtypes, while potentially bringing the program to the doorstep of commercialization.”

GBM AGILE is an international, innovative platform trial designed to more rapidly identify and confirm effective therapies for patients with glioblastoma through response adaptive randomization and a seamless Phase 2/3 design.  The trial, conceived by over 130 key opinion leaders, is conducted under a master protocol allowing multiple therapies or combinations of therapies from different pharmaceutical partners to be evaluated simultaneously.  With its innovative design and efficient operational infrastructure, data from GBM AGILE can be used as the foundation for a new drug application and biologics license application submissions and registrations to the FDA and other health authorities.

Kintara’s VAL-083 is a “first-in-class,” small molecule bifunctional alkylating agent that crosses the blood-brain barrier. VAL-083 is independent of the MGMT resistance mechanism and has been assessed in over 40 Phase 1 and Phase 2 clinical trials in multiple indications sponsored by the U.S. National Cancer Institute (NCI). Published pre-clinical and clinical data indicate that VAL-083 has activity against a range of tumor types, including lung, brain, cervical, ovarian tumors and hematologic (blood) cancers. VAL-083 has been granted Orphan Drug Designation for GBM by the FDA and EMA and has also been granted Orphan Drug Designations for medulloblastoma and ovarian cancer by the FDA. In addition, the FDA granted Fast Track Designation for VAL-083 in recurrent GBM. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer. VAL-083 has not been approved for any indications outside of China.

About Kintara

Located in San Diego, California, Kintara (Nasdaq: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).

VAL-083 is a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the NCI. Based on Kintara’s internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.

REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing. 

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and Linkedin.

About Global Coalition for Adaptive Research (GCAR)

The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) nonprofit organization uniting physicians, clinical researchers, advocacy and philanthropic organizations, biopharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases by serving as sponsor of innovative and complex trials including master protocols and platform trials. GCAR is the sponsor of GBM AGILE, an adaptive platform trial for patients with GBM – the most common and deadliest of malignant primary brain tumors. Key strategic partners for the GBM AGILE trial effort include the National Brain Tumor Society, National Foundation for Cancer Research, and Asian Fund for Cancer Research, three nonprofit organizations that are working together to provide philanthropic support as well as assistance in communicating with patients and families and inviting all others to join in supporting this innovating approach to brain tumor treatment development.

To learn more about GCAR, visit www.gcaresearch.org.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company’s clinical trials and the GBM AGILE study.  Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.  The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company’s operations and clinical trials; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies.  These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended June 30, 2020, the Company’s Quarterly Reports on Form 10-Q, and the Company’s Current Reports on Form 8-K.

CONTACTS

Investors
CORE IR
516-222-2560
[email protected]

Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
[email protected]

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/kintara-announces-initiation-of-patient-recruitment-for-val-083s-study-arm-in-the-gbm-agile-trial-301207295.html

SOURCE Kintara Therapeutics

CORK, Ireland, Jan. 13, 2021 /PRNewswire/ — Johnson Controls International plc (NYSE: JCI) announces the following webcast: 

What: Johnson Controls First Quarter Fiscal 2021 Earnings Conference Call

When: Friday, January 29, 2021 at 7:30 a.m. EST

How: The conference call for investors can be accessed in the following ways:

• Live via webcast at http://investors.johnsoncontrols.com/news-and-events/events-and-presentations Note: A slide presentation will be available that morning for downloading.
• Live via telephone (for “listen-only” participants and those who would like to ask a question) – by dialing 888-324-9610 (in the United States) or 630-395-0255 (outside the United States), passcode “Johnson Controls.”

Replay: The replay can be accessed in the following ways:

• Replay via webcast – if you are unable to participate during the live webcast, the call will be archived at http://investors.johnsoncontrols.com/news-and-events/events-and-presentations.
• Replay via telephone – by dialing 888-566-0513 (in the United States) or 203-369-3063 (outside the United States), passcode 1292, from 9:30 a.m. (ET) on January 29, 2021, until 11:59 p.m. (ET) on February 6, 2021.

About Johnson Controls:

At Johnson Controls, we transform the environments where people live, work, learn and play. From optimizing building performance to improving safety and enhancing comfort, we drive the outcomes that matter most. We deliver our promise in industries such as healthcare, education, data centers and manufacturing. With a global team of 100,000 experts in more than 150 countries and over 130 years of innovation, we are the power behind our customers’ mission. Our leading portfolio of building technology and solutions includes some of the most trusted names in the industry, such as Tyco^®, York^®, Metasys^®, Ruskin^®, Titus^®, Frick^®, Penn^®, Sabroe^®, Simplex^®, Ansul^® and Grinnell^®. For more information, visit www.johnsoncontrols.com or follow us @johnsoncontrols on Twitter.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson-controls-announces-first-quarter-2021-earnings-conference-call-webcast-301207269.html

SOURCE Johnson Controls International plc

PHOENIX, Jan. 13, 2021 /PRNewswire/ — Landsea Homes (Nasdaq: LSEA), a publicly traded residential homebuilder, announced today the acquisition of 1,067 finished single-family homesites at Eastmark in Mesa, AZ and El Cidro in Goodyear, AZ.

“We continue to strategically expand in Arizona with the recent purchases of new homesites at Eastmark and El Cidro,” said Greg Balen, Arizona regional president, Landsea Homes. “We’ve sold homes in Eastmark before and they appealed to the region’s demand for modern, quality housing at a desired price point. Mesa is one of Arizona’s most sought after cities to live and we know that these new homes at Auto Courts and Green Court will sell quickly.”

Green Court at Eastmark consists of 133 finished lots and Auto Courts at Eastmark consists of 90 finished lots, all part of Landsea Homes’ Performance Collection, offering High Performance Homes that are responsibly designed to respect the planet—with money-saving innovation to stay healthier and more comfortable, and home automation technology to make life easier.

Located in the heart of Mesa, Eastmark values connectivity and engagement with its top-rated schools, beautiful neighborhoods and innovative amenities. The large-scale community of 3,200 acres integrates new homes with employment, education, recreation and commerce. The Auto Courts and Green Court neighborhoods are just minutes away from Phoenix-Mesa Gateway Airport and located in the thriving Gateway Corridor, one of the most desirable locations within the Phoenix marketplace.

Landsea Homes also acquired 844 lots in Goodyear at the existing community, El Cidro. Featuring single-family homes ranging from 1,315 square feet to 3,240 square feet, these homes will be part of the Garrett Walker Collection, which offers homes at affordable price points. Residents will enjoy in-town living with picturesque views and easy access to I-10.

“With these new homes at El Cidro, we’re proud to provide homeowners with the perfect opportunity to live in their element,” added Balen.

For more information about Landsea Homes’ Arizona communities, visit www.landseahomes.com.

About Landsea Homes

Landsea Homes Corporation (Nasdaq: LSEA) is a publicly traded residential homebuilder based in Newport Beach, CA that designs and builds best-in-class homes and sustainable master-planned communities in some of the nations most desirable markets. The company has developed homes and communities in New York, Boston, New Jersey, Arizona, and throughout California in Silicon Valley, Los Angeles and Orange County.

An award-winning homebuilder that builds suburban, single-family detached and attached homes, mid-and high-rise properties, and master-planned communities, Landsea Homes is known for creating inspired places that reflect modern living and provides homebuyers the opportunity to “Live in Your Element.” Our homes allow people to live where they want to live, how they want to live – in a home created especially for them.

Driven by a pioneering commitment to sustainability, Landsea Homes’ High Performance collection features homes that are responsibly designed to take advantage of the latest innovations with home automation technology supported by Apple®. Homes in this collection include features that make life easier and provide energy savings that allow for more comfortable living at a lower cost through sustainability features that contribute to healthier living for both homeowners and the planet.

Our Garrett-Walker collection offers unique, affordably priced and value-based single-family homes in some of the nation’s fastest growing and most desirable markets. Homebuyers enjoy the confidence of owning a quality home that provides lasting value. One of the most trusted brands in the region, this collection continues to attract everyone from first-time homeowners to those seeking more room for their growing families.

Led by a veteran team of industry professionals who boast years of worldwide experience and deep local expertise, Landsea Homes is committed to positively enhancing the lives of our homebuyers, employees and stakeholders by creating an unparalleled lifestyle experience that is unmatched.

For more information on Landsea Homes, visit: www.landseahomes.com.

View original content:http://www.prnewswire.com/news-releases/landsea-homes-acquires-over-1-000-single-family-homesites-in-arizona-301207304.html

SOURCE Landsea Homes

LOVELAND, Colo., Jan. 13, 2021 /PRNewswire/ — Heska Corporation (NASDAQ: HSKA – News; “Heska” or the “Company”), a leading global provider of advanced veterinary diagnostic and specialty products, announced today that the Company has entered into an agreement (the “Agreement”) to acquire 100% of Lacuna Diagnostics, Inc. (“Lacuna”), a pioneer and market leader in point-of-care diagnostics digital cytology technology and telemedicine services.

Founded in 2016 and headquartered in Fort Collins, Colorado, Lacuna is a first-to-market digital telemedicine cytology platform that increases the standard of care veterinarians provide for pets by providing nearly real-time interpretation of cases by an expert network of board-certified clinical pathologists. Lacuna’s revolutionary software, workflow, and artificial intelligence data technology facilitate fast, accurate and comprehensive results from samples taken at the point of care and instantly transmitted to Lacuna’s team of board-certified experts. Lacuna improves veterinarian accuracy and confidence and accelerates positive healthcare outcomes by dramatically decreasing the wait times and environmental pollution associated with traditional central reference lab pathology services. With a global team of over 25 pathologists located throughout multiple time zones in the United States, Canada, Europe, New Zealand and Australia, Lacuna has interpreted over 25,000 cases and counting.

“The addition of Lacuna is the official starting point for Heska’s entry into providing clinical specialty services to further support our stated goal to double the product and revenue streams we serve,” commented Heska’s Chief Executive Officer and President, Kevin Wilson. “We are excited to welcome the wonderful leadership, people, and culture of Lacuna,” continued Mr. Wilson. “Lacuna has created a foundation of amazing technology, processes, and expert clinical teams to deliver specialist-level diagnostics, in minutes rather than days. We are excited to expand the scope and availability of these life-saving telemedicine specialty services by offering them alongside our other Heska technologies, through our hundreds of Heska field experts, and to thousands of our current point of care customers and other veterinarians.”

Lacuna’s Co-Founder and Co-Chief Executive Officer, Aaron Wallace, commented, “Lacuna has always focused on providing quality and trusted reporting to our veterinarians. Heska will advance this promise in every way while also supporting a larger reach to positively impact more pet patients and veterinary teams.”

The Acquisition is expected to close in the first quarter 2021, subject to the satisfaction or waiver of closing conditions set forth in the Agreement, including customary closing conditions.

Mr. Wilson will provide more information about this announcement and other growth initiatives at the J.P. Morgan Healthcare Conference at 2:00 p.m. ET on Wednesday, January 13, 2021. A live audio-only version of the presentation and question and answer session will be available to non-registered attendees at  Heska Audio-Only J.P. Morgan Conference Presentation. The webcast and presentation will be archived on Heska’s website shortly after the event and a replay will be available for 90 days following the conference.

About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health.

Forward-Looking Statements
This document contains forward-looking information related to the Company. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. All of the statements in this document, other than historical facts, are forward-looking statements and are based on a number of assumptions that could ultimately prove inaccurate and cause actual results to materially deviate from forward-looking statements. Forward-looking statements in this document include, among other things, statements with respect to future financial and operating results and strategic goals, the expected timing of the Acquisition and its anticipated benefits.  Such statements are subject to risks and uncertainties, including, but not limited to, uncertainties related to the closing of the Acquisition; the ability to achieve the anticipated benefits of the Acquisition uncertainties related to any product’s ability to perform and be recognized as anticipated, in particular when such product is under development; uncertainties related to Heska’s ability to sell and market its products in an economically sustainable fashion, including related to varying customs, cultures, languages and sales cycles and uncertainties with foreign political and economic climates; and the Company’s ability to integrate the acquired Lacuna business within its existing operations; and new product development and release schedules. Other factors that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements are set forth under “Risk Factors” in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

View original content to download multimedia:http://www.prnewswire.com/news-releases/heska-corporation-to-acquire-lacuna-diagnostics-a-pioneer-and-market-leader-in-point-of-care-digital-cytology-301207213.html

SOURCE Heska Corporation

WOODLAND PARK, N.J. and CHICAGO, Jan. 13, 2021 /PRNewswire/ — Xcel Energy will use a new wireless telecommunications tool that can help the company respond more quickly to local electric outages and support advanced grid ‘smart meters’ that will provide more information to customers about their energy use.

The 900 MHz private wireless broadband network will be installed at two existing Xcel Energy sites in Minneapolis. In addition to helping launch advanced grid efforts, the network will allow Xcel Energy to provide cyber protection to critical infrastructure and could eventually be expanded to support automated technology throughout metro and remote rural locations. The network will be developed by Motorola Solutions (NYSE: MSI) using Anterix’s (NASDAQ: ATEX) 900 MHz spectrum. 

“Xcel Energy is supporting our customers by introducing new technology that will enable several improvements. The addition of tools in the future will give our customers greater insight into their energy use, help us respond more quickly to local power outages, and provide enhanced communication technology to support our field operations,” said Tim Peterson, Chief Information Officer and Senior Vice President, Xcel Energy. “This new telecommunications technology will provide a basis for new solutions, which can improve grid operations, enhance system security, and ultimately deliver a better experience for our customers.”

The availability of wireless broadband spectrum in the 900 MHz band resulting from the FCC’s recent actions now allows critical infrastructure providers, such as Xcel Energy, to deploy private networks that enable secure and resilient electric grids. Motorola Solutions’ LXN 7900 fixed LTE 900 MHz infrastructure, in combination with its Citizens Broadband Radio Service (CBRS)-based Nitro™ network, will enable the seamless exchange of voice and data across private LTE broadband and existing LMR networks. A future roll-out of a broader private LTE deployment could be accelerated by leveraging Xcel Energy’s existing investments in LMR site locations and infrastructure to support existing and new grid-of-the-future applications.

“We look forward to working with Xcel Energy as they catalogue the benefits of private broadband for voice, data and IoT communications,” said Scott Schoepel, Vice President, Global Enterprise, Motorola Solutions. “As utility operations become increasingly complex and the electrical grid ever more automated, private broadband will support the necessary data speeds, capacity and security, as well as the technology and analytics, needed to support modern and resilient utility infrastructure.”

“At Anterix, our goal is to deliver transformative broadband that enables the modernization of critical infrastructure for the utility sector. We are excited to work with Xcel Energy as they continue their long-standing commitment to leverage advanced technology to enable better service to their customers,” said Rob Schwartz, President & CEO of Anterix. “In partnership with Motorola Solutions, we plan to demonstrate the efficiency, resiliency and security provided by private LTE and validate how private LTE can not only support modernization of the grid and operations for Xcel Energy customers in Minneapolis, but also pioneer the future of broadband communications for the entire utility industry.”

About Anterix

At Anterix, we are focused on delivering transformative broadband that enables the modernization of critical infrastructure for the energy, transportation, logistics and other sectors of our economy. As the largest holder of licensed spectrum in the 900 MHz band, with nationwide coverage throughout the contiguous United States, Hawaii, Alaska and Puerto Rico, we are uniquely positioned to enable the private LTE broadband solutions that support secure, resilient and customer-controlled operations. 

About Motorola Solutions

Motorola Solutions is a global leader in mission-critical communications and analytics. Our technology platforms in mission-critical communications, command center software, video security & analytics, bolstered by managed & support services, make communities safer and help businesses stay productive and secure. At Motorola Solutions, we are ushering in a new era in public safety and security. Learn more at www.motorolasolutions.com.

About Xcel Energy

Xcel Energy (NASDAQ: XEL) provides the energy that powers millions of homes and businesses across eight Western and Midwestern states. Headquartered in Minneapolis, the company is an industry leader in responsibly reducing carbon emissions and producing and delivering clean energy solutions from a variety of renewable sources at competitive prices. For more information, visit xcelenergy.com or follow us on Twitter and Facebook.

Media Contacts:
Anterix
Natasha Vecchiarelli
Director of Investor Relations & Corporate Communications
973-531-4397

Anterix
Hill+Knowlton Strategies
James Fuller
Executive Vice President
240-393-1369

Motorola Solutions
Michelle Quivey   
(312) 218-0010
[email protected] 

Xcel Energy
Randy Fordice
612-215-5300
[email protected]

Forward-looking Statements

Any statements contained in this press release that do not describe historical facts are forward-looking statements as defined under the Federal securities laws. These forward-looking statements include statements regarding: (i) Xcel’s proposed pilot program will demonstrate the benefits of utilizing Anterix’s 900 MHz spectrum to deploy a private LTE network in its service area, (ii) Xcel will elect to license Anterix’s 900 MHz spectrum following its pilot program, and (iii) Anterix will be successful in obtaining Broadband licenses in Xcel’s service area.  Any such forward-looking statements are based on Anterix’s current expectations and are subject to a number of risks and uncertainties that could cause its actual future results to differ materially from its current expectations or those implied by the forward-looking statements, including: (i) Xcel’s pilot program may not be successful or may not demonstrate sufficient benefits to cause Xcel to lease Anterix’s 900 MHz spectrum; (ii) Anterix may not be able to obtain broadband licenses on favorable terms and on a timely basis, or at all; (iii) Anterix may not be successful in commercializing its spectrum assets to its targeted critical infrastructure and enterprise customers; (iv) Anterix has a limited operating history with its proposed business plan, which makes it difficult to evaluate its prospects and future financial results; and (v) the ongoing coronavirus outbreak could adversely impact Anterix’s business, including its broadband licensing and commercialization efforts. These risks and uncertainties and other factors that may affect Anterix’s future results of operations are identified and described in more detail in its filings with the Securities and Exchange Commission (the “SEC”), including its Quarterly Report for the quarter ended September 30, 2020, filed with the SEC on November 16, 2020. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by applicable law, Anterix does not intend to update any of the forward-looking statements to conform these statements to actual results, later events or circumstances, or to reflect the occurrence of unanticipated events.


MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license. All other trademarks are the property of their respective owners. ©2021 Motorola Solutions, Inc. All rights reserved.

View original content to download multimedia:http://www.prnewswire.com/news-releases/xcel-energy-to-launch-initial-deployment-of-900-mhz-wireless-private-broadband-301207315.html

SOURCE Anterix Inc.

VANCOUVER, BC, Jan. 13, 2021 /PRNewswire/ – Defense Metals Corp. (“Defense Metals” or the “Company“) (TSXV: DEFN) (OTCQB: DFMTF) (FSE: 35D) is pleased to announce that it has commissioned the Saskatchewan Research Council (“SRC“) to complete an X-Ray Transmission (“XRT“) sorting amenability study with respect to mineralized feed sourced from its 1,708 hectare (4,220 acre) Wicheeda Rare Earth Element (REE) Property (“Wicheeda“) located close to existing infrastructure near Prince George, British Columbia (BC).

Defense Metals and SRC have been awarded National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) funding, a Government of Canada funded program mandated to provide financial support for technology innovation. Funding awarded under the NRC IRAP will cover approximately 70% of the estimated cost of the XRT amenability study test-work.

The Wicheeda project has indicated mineral resources of 4,890,000 tonnes averaging 3.02% LREO (Light Rare Earth Elements) and inferred mineral resources of 12,100,000 tonnes averaging 2.90% LREO¹. Flotation pilot-plant processing of a 26-tonne bulk sample of Wicheeda REE material yielded a mineral concentrate averaging 7.4% NdPr oxide (neodymium-praseodymium) critical magnet metals².

The objective of the SRC amenability study is to investigate XRT sorting for the purpose of upgrading Wicheeda REE mineralization prior to downstream processing.  Sensor based sorting has several advantages when applied to REE mining projects in that beneficiation occurs without water and with reduced grinding requirements. The investigation will assess how much gangue can be removed from the head feed. The investigation will then carry out an iterative study of different sorting sizes to process in the XRT sorter assessing both the grade of the upgraded concentrate and the grade of the waste for economic studies whereby the optimum operational parameters can be determined. 

XRT sorting has the potential to realize several significant project benefits including:

• Relatively low-cost gangue (unmineralized waste) removal and volume reduction at the front-end of the Wicheeda REE processing stream;
• Potential to have a significant positive benefit on downstream flotation and hydrometallurgical processes via reduced water, heating, and reagent consumption costs; and
• Depending on the success of the test-work these reductions may contribute to overall lower size / throughput and capital cost of potential future commercial REE concentration and refining facilities at Wicheeda.

Craig Taylor, CEO comments:

“Defense Metals looks forward to investigating the potential of low-cost front-end upgrading of Wicheeda REE mineralization via XRT sorting. We have already demonstrated the ability to produce a greater than 50% REO concentrate during flotation pilot plant test-work and we hope unlocking the benefits of XRT sorting will yield downstream processing benefits of increased head grade, flotation concentrate, and hydrometallurgical feed streams”.

Details of XRT Study Methodology

X-ray Transmission (XRT) Analysis:

The XRT investigation requires the selection of large samples containing both gangue and REE mineralization for analysis. The samples are analysed using:

• Dual energy X-ray transmission measurements (DE-CT), and
• QEMSCAN for calibration and mineral identification and modal mineralogy.

Photographs of the polished QEMSCAN samples are used to verify the atomic differences measured by DE-CT. The modal mineralogy is used to determine REE grades.

Image Analysis:

The DE-CT images are analyzed using different sized grids to determine how much gangue can be removed for a range of particle sizes. This process determines the upgrading possibilities for different sorting sizes, the grade of the concentrate and the grade of the waste. 

Wicheeda REE Project

The Wicheeda REE project has indicated mineral resources of 4,890,000 tonnes averaging 3.02% LREO (Light Rare Earth Elements) and inferred mineral resources of 12,100,000 tonnes averaging 2.90% LREO³.

Qualified Person

The scientific and technical information contained in this news release as it relates to the Wicheeda REE Property has been reviewed and approved by Kristopher J. Raffle, P.Geo. (BC) Principal and Consultant of APEX Geoscience Ltd. of Edmonton, AB, a director of Defense Metals and a “Qualified Person” as defined in National Instrument 43-101 – Standards of Disclosurefor Mineral Projects. 

About Defense Metals Corp.

Defense Metals Corp. is a mineral exploration company focused on the acquisition of mineral deposits containing metals and elements commonly used in the electric power market, military, national security and the production of “GREEN” energy technologies, such as, high strength alloys and rare earth magnets. Defense Metals has an option to acquire 100% of the 1,708 hectare Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding Forward Looking Information

This news release contains “forward–looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, statements relating to the Company’s plans for its Wicheeda project, XRT study and the expected benefits and results therefrom, the technical, financial and business prospects of the Company, its project and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of rare earth elements, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including those filed under the Company’s profile on SEDAR at www.sedar.com. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather conditions, failure to maintain or obtain all necessary government permits, approvals and authorizations, failure to maintain community acceptance (including First Nations), decrease in the price of rare earth elements, the impact of Covid-19 or other viruses and diseases on the Company’s ability to operate increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward–looking statements or forward–looking information, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/defense-metals-corp-and-src-investigate-xrt-ammenability-of-wicheeda-rare-earth-element-mineralization-301207277.html

SOURCE Defense Metals Corp.

NAPA, Calif., Jan. 13, 2021 /PRNewswire/ — Silicon Valley Bank (SVB), the bank of the world’s most innovative companies and their investors, today released its 2021 State of the Wine Industry Report. Now in its 20^th year, this authoritative annual report assesses current conditions in the wine industry and provides a unique forecast for the year ahead based on proprietary research and economic and behavioral trends.

Highlights and predictions from the 2021 wine industry conditions survey and report:

• As the hospitality, travel and entertainment industries rebuild, there will be strong consumer demand and a bounce in overall sales that will gain momentum in 2021, but may not be sustainable into 2022.
• The wine sales growth rate across all price segments has been declining for many years. The wine industry will need a national marketing organization to deliver a unified consumer message.

Price

• Overall bottle pricing should hold in both off- and on-premise sales, as well as in the direct-to-consumer channels, as demand for alcohol and special occasions undergoes a temporary growth spurt in 2021.
• Premiumization, a move to higher-priced wine, is nearing an apex but will continue into 2021 as deferred celebrations and reduced supply stall the expected change.

Sales Channels

• Retailers with existing ecommerce strategies will have a strong 2021. Online sales could represent 20 percent of an average winery’s sales within 5 years.
• Surviving restaurants will come out of the pandemic financially damaged and will require investment for new revenue-generating strategies. Wine sales through restaurant channels will not recover to pre-COVID levels in 2021, nor for many years.
• Off-premise grocery sales will show year-over-year declines.
• Wineries with direct-to-consumer models will focus on COVID-era sales strategies in the front half of the year and will likely finish 2021 with strong tasting room sales.

Supply

• When 2020 totals are calculated, we forecast that California will have crushed 3.3 million tons, resulting in the smallest harvest since 2011. The Pacific Northwest harvests in both Oregon and Washington will also come in smaller than normal.
• Wine supply in California is largely in balance after starting the year with an acute over-supply. With limited growth in volume and an expected reduction in wine sold at grocery stores, a large 2021 harvest could put the industry back into a position of being over-supplied once again.

Demand

• Retiring baby boomers will moderate their wine purchasing, both in price and volume, as they age. Online sales to boomers at home will be a growth channel.
• The under-40 cohorts are where the wine industry will find growth in the next decade with 30.3 million Americans crossing age 40 in the next 5 years. The wine industry has to evolve its messaging to attract this new consumer.

“2021 will be a year of two phases for the wine industry: the continuation of a COVID-restricted mode during the first part of the year, followed by a gradual reopening of businesses and a resurgence in hospitality, travel and entertainment made possible by the success of widespread vaccinations,” said Rob McMillan, founder of Silicon Valley Bank’s Wine Division and author of the report.

“Those wineries that evolved in 2020, were creative in their sales channels, and recognize the permanent societal changes that will impact the industry forever will be successful in meeting the anticipated demand post-vaccine and beyond.”

SVB will host a live videocast with Rob McMillan to discuss the annual report and the state of the wine industry on January 13, 2021 at 9:00 a.m. PT with Amy Hoopes, President of Wente Family Estates; Devin Joshua, Managing Director of Merryvale Vineyards; Erik McLaughlin, CEO of Metis; and Paul Mabray, CEO of Pix.wine. Register for the live event here. A replay of the discussion will be available after the event.

Read the full 2021 State of the Wine Industry report here: svb.com/wine-report

About Silicon Valley Bank

For more than 35 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast. SVB provides targeted financial services and expertise through its offices in innovation centers around the world. With commercial, international and private banking services, SVB helps address the unique needs of innovators. Learn more at svb.com.

Silicon Valley Bank’s Wine Division

Founded in 1994, SVB’s Wine Division offers financial services and strategic advice to premium vineyards and wineries. With one of the largest banking teams in the country dedicated to the wine industry, SVB’s Wine Division has offices in Napa, Sonoma and Portland, and primarily serves clients in the fine wine producing regions along the West Coast of the United States. Learn more at svb.com/premium-wine-banking/

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/silicon-valley-bank-predicts-the-wine-industry-will-see-a-spike-in-demand-when-consumers-celebrate-postponed-life-events-in-2021-301207294.html

SOURCE Silicon Valley Bank

VANCOUVER, BC, Jan. 13, 2021 /CNW/ – (OTCB: FOGCF) (CSE: FOG) (FRA: MUU3) Fogchain Corp. (“Fogchain” or the “Company”) is pleased to announced that it has entered into a letter of intent (“LOI”) dated January 12, 2021 with Avisa Pharma Inc. (“Avisa”) pursuant to which Fogchain will acquire all of the outstanding shares of Avisa (the “Transaction”) pursuant to an arm’s length business combination transaction, which will constitute a reverse takeover of the Company by Avisa within the meaning of the policies of the Canadian Securities Exchange Inc. (the “CSE”). The resulting issuer (the “Resulting Issuer”) upon completion of the Transaction will change its name to some other name as acceptable to the parties and will operate the current business of Avisa Pharma Inc.

Transaction

Pursuant to the Transaction, all of the issued and outstanding common stock in the capital of Avisa (the “Avisa Shares”) will be exchanged for common shares in the capital of the Company which will result in Avisa becoming a wholly owned subsidiary of the Company. Under the terms of the LOI, upon completion of the Transaction, the current shareholders of the Company will retain approximately 10% of the issued and outstanding share capital of the Resulting Issuer on a fully diluted basis, inclusive of any securities which may be issued pursuant to any financing which Avisa may pursue concurrent with the Transaction.

The final structure of the Transaction will be determined by the parties following the receipt of tax, corporate and securities law advice. The Transaction is an arm’s length transaction and pursuant to the terms of the LOI it is anticipated that the definitive agreement (the “Definitive Agreement”) in respect of the Transaction will be signed on or before February 1, 2021.

Completion of the Transaction is subject to a number of conditions, including but not limited to the following key conditions:

• execution of the Definitive Agreement;
• completion of mutually satisfactory due diligence; and
• receipt of all required regulatory, corporate and third-party approvals, including the approval of the CSE and the shareholders of the Company and Avisa (if required) and the fulfillment of all applicable regulatory requirements and conditions necessary to complete the Transaction.

New Board and Management

Effective on the closing of the Transaction it is anticipated that the current members of the board of directors of the Company (the “Board”) and the current management of the Company will resign. With respect of the Board, the current members will upon completion of the Transaction be replaced by nominees to the Board appointed by Avisa (the “Nominees”) and the existing management team of Avisa will replace the current management of the Company.

Shareholder Approval

Prior to the completion of the Transaction, the Company will call a special meeting of its shareholders for the purpose of approving, among other matters (i) the election of the Nominees to the Board; and (ii) the change of name of the Company.

Avisa Pharma Inc.

Established in 2010, Avisa is a private medical device company with its head office in Santa Fe, New Mexico and incorporated under the laws of the State of Delaware. Avisa has developed a quantitative, point-of-care diagnostic breath test known as the Avisa BreathTest (“ABT“) for rapidly detecting bacterial pneumonia and pulmonary infections in approximately 10 minutes.  The ABT has the potential to be a more accessible, faster and cost-effective detection method than presently used in the healthcare sector. The ABT is a validated clinical stage test with existing technology. Avisa currently has an intellectual property portfolio of 11 patents issued and registered and 3 patents pending. Avisa has raised approximately US$16 million to date.

Learn more at www.avisapharma.com

Fogchain Corp.

FogChain is a fully integrated, end-to-end software development life cycle (SDLC) and quality assurance solutions provider. With its high-performance application development, testing and monitoring platform, Trident, FogChain’s suite of services and technology provides application development at scale with greater speed, greater efficiency and at a lower cost.

Learn more at www.fogchaininc.com

Forward-Looking Information

This news release contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information.  Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning the Transaction. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. These assumptions, risks and uncertainties include, among other things, the assumption that the Company will receive the approval of its shareholders and the CSE in respect of the Transaction. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Factors that could cause the actual results to differ materially from those in the forward-looking statements include, failure to obtain the final approval of the CSE, among other factors.

The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

The CSE nor its market regulator does not accept responsibility for the adequacy or accuracy of this news release. The CSE has in no way passed upon the merits of the proposed Transaction and has neither approved nor disapproved the contents of this news release.

SOURCE FogChain Corp.

MONTRÉAL, Jan. 13, 2021 /CNW Telbec/ – BTB Real Estate Investment Trust (TSX: BTB.UN) (“BTB” or the “REIT“) announced today that the monthly cash distribution for the month of January 2021 is $0.025per unit, representing $0.30per unit on an annualized basis. The cash distribution will be paid February 16^th, 2021 to unitholders of record on January 29^th, 2021.

ABOUT BTB

BTB is a real estate investment trust listed on the Toronto Stock Exchange. BTB is an important owner of properties in eastern Canada. As at January 13^th, 2021 BTB owns 64 retail, office, and industrial properties for a total leasable area of approximately 5.3 million square feet. As of September 30^th, 2020 BTB’s approximate total asset value is approximately $946M.

BTB’S OBJECTIVES

1. Generate stable monthly cash distributions that are reliable and fiscally beneficial to unitholders;
2. Grow the Trust’s assets through internal growth and accretive acquisitions in order to increase distributable income and therefore refund distributions;
3. Optimize the value of its assets through the dynamic management of its properties in order to maximize the long-term value of its properties and therefore, its units.

BTB offers a distribution reinvestment plan to unitholders whereby the participants may elect to have their monthly cash distribution reinvested in additional units of BTB at a price based on the weighted average price for BTB’s Units on the Toronto Stock Exchange for the five trading days immediately preceding the distribution date, discounted by 3%.

For more detailed information, visit BTB’s website at www.btbreit.com.

SOURCE BTB Real Estate Investment Trust